Which less aggressive induction therapy regimens for mantle cell lymphoma (MCL) are recommended by NCCN?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Less aggressive induction regimens include the following:

  • Bendamustine + rituximab
  • VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone)
  • Cladribine + rituximab (category 2B)
  • CHOP + rituximab
  • Lenalidomide + rituximab
  • Modified rituximab-hyperCVAD in patients older than 65 

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!